Oppenheimer Lifts Target on Celldex Therapeutics (CLDX) on Final Phase IIb CDX-011 Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Oppenheimer Lifts Target on Celldex Therapeutics (CLDX) on Final Phase IIb CDX-011 Data

Celldex (CLDX) Reports Some Statistically Significant Data from CDX-011 Phase 2

December 10, 2012 9:13 AM EST

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced final results from the Companys randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer. CDX-011 is an antibody-drug conjugate that targets and binds to GPNMB, a specific protein that is expressed in breast cancer which promotes the migration, invasion and metastasis of the disease. It is also highly expressed in triple negative breast cancers where it is associated with increased risk of recurrence. The results presented today at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium confirm... More

Jefferies Lifts Target on Celldex Therapeutics (CLDX) to $9 on Compelling CDX-011 OS Data

December 10, 2012 8:17 AM EST

Jefferies boosted its price target on Buy-rated Celldex Therapeutics (NASDAQ: CLDX) from $7 to $9.

The firm comments, "CLDX presented positive CDX-011 OS data for TNBC+hGPNMB pts in EMERGE with supportive PFS data, potentially enabling a follow-on accelerated PII trial. Encouraging OS data... More